Market research
PYPD PolyPid
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 101M
- P/E ratio
- Not available
- Analyst target
- 11.75
- Dividend yield
- Not available
- Beta
- 1.39
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- IL0011326795
- Market cap
- 101M
- P/E ratio
- Not available
- Analyst target
- 11.75
- Dividend yield
- Not available
- Beta
- 1.39
About
About PolyPid
PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. The company is also developing OncoPLEX, which is in preclinical stage for the treatment of intra-tumoral cancer. The company has a research and development collaboration with ImmunoGenesis, Inc. for the development of formulations to treat solid tumors. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the PYPD discussion.
5 years, 4 months ago
PolyPid Ltd is currently in a long term downtrend where the price is trading 12.9% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Based on the above factors, PolyPid Ltd gets an overall score of 1/5.